SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to heightened speculation surrounding a potential buyout or major partnership, as investors track ongoing M&A activity in the weight-loss drug sector and analyze the competitive potential of VK2735 against industry leaders. The community is actively discussing the company's clinical trial progress and the perceived undervaluation of its obesity pipeline, with many members dismissing recent share price volatility as market noise in anticipation of upcoming data readouts.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl Capital is facing downward pressure following the company's decision to restrict investor withdrawals from a key private credit fund and the subsequent unloading of over a billion dollars in loan assets. While management frames the shift as a move to accelerate capital returns, the community is actively debating whether this signals a broader liquidity crunch within the private credit sector or represents a manageable adjustment to fund operations.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors digest the FDA approval of Foundayo, the company's first oral GLP-1 weight-loss pill, which significantly intensifies the competitive landscape against Novo Nordisk. Community discussion is heavily focused on the clinical efficacy and side-effect profile of Foundayo versus oral Wegovy, while broader sentiment remains polarized between enthusiasm for Lilly's commercial execution and concerns regarding supply chain hurdles and intensifying pricing competition.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is currently trending as a defensive heavyweight, with investors monitoring the company's strong clinical pipeline, including positive oncology data for multiple myeloma, while legal teams remain focused on ongoing talc-related litigation. The community is actively discussing JNJ's role as a reliable dividend compounder and evaluating the potential impact of long-term healthcare demand versus structural legal liabilities.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending as investors closely watch upcoming earnings and scrutinize the new leadership's ability to manage high debt levels while balancing subscriber growth against competitive market pressures. The community remains divided, with some betting on a defensive dividend play and share buybacks, while others express frustration over persistent service quality issues and skepticism toward the company's long-term growth narrative.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is trending as energy markets grapple with acute supply volatility and geopolitical instability centered on the Strait of Hormuz. Investors are actively debating whether current supply-side constraints and record-high commodity prices will sustain long-term sector gains or trigger broader economic demand destruction.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased social and trading activity driven by news of its quantum-resistant technology being cited by Google researchers, alongside anticipation for US regulatory clarity. The community remains divided between long-term holders optimistic about its institutional utility and active traders debating the impact of ongoing market volatility.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

The United States Natural Gas Fund is facing significant volatility as traders react to shifting weather forecasts and intense market pressure following a sharp sell-off. Community sentiment remains deeply divided, with many market participants actively debating the impact of seasonal demand transitions and the risks of holding highly leveraged products.

KLA Corp. engages in the supply of process control and yield management solutions for the semiconductor and related nano-electronics industries. The company operates through the following segments: Semiconductor Process Control, Specialty Semiconductor Process, and PCB, Display and Component Inspection. The Semiconductor Process Control segment provides a comprehensive portfolio of inspection, metrology and data analytics products and related services. The Specialty Semiconductor Process segment develops and sells advanced vacuum deposition and etching process tools. The PCB, Display and Component Inspection segment enables electronic device manufacturers to inspect, test and measure PCBs, flat panel displays and ICs to verify their quality. Its products include manufactured chips, reticle, packaging, surface profilers, nanochemical testers, KT pro equipment, and compound semiconductors. The company was founded on July 9, 1975 and is headquartered in Milpitas, CA.

KLA Corp.

KLA Corp. is currently trending as investors weigh strong capital return initiatives, including aggressive share buybacks, against ongoing concerns regarding semiconductor sector volatility and geopolitical supply chain risks. The community remains closely divided between the bull case, centered on KLA's essential role in advanced process control for the AI roadmap, and the bear case, driven by macro uncertainty and equipment delivery headwinds.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing heightened community interest as investors debate the potential for a strategic acquisition, with many pointing to the company's significant cash position and active boardroom discussions. While some traders are focused on technical indicators and speculative M&A targets like SNAP, others are expressing frustration over the lack of immediate corporate catalysts and are pushing for clarity on the CEO's compensation and future growth strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments occurring in the oncology field.”</li><li>BioNTech is now looking to strengthen its oncology portfolio as it pivots away from its Covid-19 vaccine Comirnaty developed with Pfizer.&nbsp;</li><li>BioNTech’s oncology pipeline comprises late-stage candidates spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies.</li></ul>Shares of BioNTech SE (BNTX) rose 3% on Friday after Goldman Sachs upgraded the stock to ‘Buy’ from ‘Neutral’.Goldman also raised the price target on the stock to $142, up from $115, according to TheFly. The new price target represents a potential upside of about 34% from the stock’s closing price on Thursday. &nbsp;<h2 class="st-heading-2">Goldman’s Rationale</h2>With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments occurring in the oncology field” and uniquely positioned to develop novel combination approaches to transform cancer care.Data unlocks in 2026 could position the company with “a leading foothold in an emerging wave of new product cycles,” the analyst added.<h2 class="st-heading-2">Pipeline</h2>BioNTech is now looking to strengthen its oncology portfolio as it pivots away from its Covid-19 vaccine Comirnaty developed with Pfizer.BionTech’s oncology pipeline comprises late-stage candidates spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. It is also developing several combination approaches.In 2026, the company expects seven late-stage data readouts, and also looks forward to applying to the U.S. Food and Drug Administration (FDA) for approval of its drug T-Pam in endometrial cancer. BioNTech hopes to become a multi-product oncology company by 2030.The company, however, does not currently anticipate the recognition of revenues from the sale of any oncology products in 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BNTX stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user, however, highlighted concerns with the company’s recent acquisition of CureVac. BioNTech closed the acquisition of CureVac in December after<a href="https://stocktwits.com/news-articles/markets/equity/biontech-to-acquire-curevac-in-all-stock-deal-valued-at-1.25-billion/chlXz8nRb6u"> announcing </a>the all-stock deal in June to support its oncology strategy.<stembedurl>https://www.stocktwits.com/taxplanr/message/642106083</stembedurl><a href="https://stocktwits.com/symbol/BNTX">BNTX stock</a> has fallen 3% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/genmab-reports-mixed-results-from-late-stage-trial-of-lymphoma-drug/cmUmGfeR4Bt">Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio

Goldman raised the price target on BioNTech SE to $142, up from $115.

Equity

Goldman Sachs ETF Trust - Goldman Sachs Innovate Equity ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$68.94
Prev Close	$68.91
Open	$68.66
Dividend Yield	N/A
50-Day Moving Average	$71.75
Beta	N/A
Avg. Volume	2,784.33
PE Ratio	N/A

52-Week High	$76.80
52-Week Low	$50.32
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

GINN
Goldman Sachs ETF Trust - Goldman Sachs Innovate Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest GINN News

GINNGoldman Sachs ETF Trust - Goldman Sachs Innovate Equity ETF